If I can go through the motions in order, it might be helpful.
In regard to the first motion, as a clinician I am obviously supportive of this motion.
On the second motion, I believe we have attempted to have very broad representation in our consultation with the nuclear medicine physicians. The Canadian Association of Nuclear Medicine was actively involved in my appointment and in the conversations around my appointment, and Dr. Urbain was on the panel that agreed to my appointment.
I think the investment is important, and we have clearly started seeing that. The CIHR and the NRCan panel are important elements of that item. I think the motion that was proposed by the president of the CMA, recognizing and appreciating the responses of the clinical community, is appropriate and I enthusiastically endorse that motion.
I think the final motion, which is looking at new technologies and, most importantly, new ways of producing technetium-99m, which may not necessarily be reactor-based, is a very important one, and clearly this is now before the NRCan panel.